- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Verenigd Koninkrijk
- Great Ormond Street Hospital
-
-
-
-
California
-
Stanford, California, Verenigde Staten, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32611
- University of Florida
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- UTSW
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female ≥ 2 years
- Documented diagnosis of Arginase 1 deficiency
- Adequate organ function as defined by laboratory assessment
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures
Exclusion Criteria:
- Transfusion of ≥ 2 units of RBCs within 60 days
- Active infection requiring systemic treatment
- Known infection with HIV, Hep B or Hep C
- Unstable hyperammonemia requiring hospitalization within 14 days
- Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
- If female, is lactating or breast feeding
PART 2 INCLUSION CRITERION:
1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: AEB1102
AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks. Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy. |
modified human arginase I
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With Adverse Events Related to ECGs
Tijdsspanne: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing ECG results was through assessing AEs related to ECGs. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
|
Number of Participants With Adverse Events Related to Clinical Laboratory Results
Tijdsspanne: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
Tijdsspanne: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Plasma Arginine Concentrations After AEB1102 IV
Tijdsspanne: 168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
Plasma arginine concentration post dose AEB1102 IV |
168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
Tijdsspanne: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
Tijdsspanne: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
Tijdsspanne: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
Tijdsspanne: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Publicaties en nuttige links
Algemene publicaties
- Diaz GA, Schulze A, McNutt MC, Leao-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26.
- Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005 Mar;84(3):243-51. doi: 10.1016/j.ymgme.2004.11.004. Epub 2004 Dec 19.
- Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011 Jun;4(3):138-46. doi: 10.1593/tlo.10265. Epub 2011 Jun 1.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Metabolisme, aangeboren fouten
- Genetische ziekten, aangeboren
- Metabole ziekten
- Hersenziekten, metabolisch, aangeboren
- Hersenziekten, Metabool
- Aminozuurmetabolisme, aangeboren fouten
- Ureumcyclusstoornissen, aangeboren
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Voedings- en stofwisselingsziekten
- Hyperargininemie
Andere studie-ID-nummers
- CAEB1102-101A
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .